Opportunistic enteroviral infections in MS patients treated with anti-CD20 therapies

Abstract

Get full access to this article

View all access options for this article.

References

Vollmer

Wallach

Corboy

, et al. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol 2020; 7(9): 1477–1487.

Hauser

Kappos

Montalban

, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology 2021; 97(16): e1546–e1559.

Stogbauer , et al.

McGill

Griffiths

Bonnett

, et al. Incidence, aetiology, and sequelae of viral meningitis in UK adults: A multicentre prospective observational cohort study. Lancet Infect Dis 2018; 18(9): 992–1003.

Defres

Tharmaratnam

Michael

, et al.; ENCEPH UK Study Group. Clinical predictors of encephalitis in UK adults: A multi-centre prospective observational cohort study. PLoS ONE 2023;18: e0282645.

Shen

Chiu

Chow

, et al. MR imaging findings of enteroviral encephaloymelitis: An outbreak in Taiwan. AJNR Am J Neuroradiol 1999; 20(10): 1889–1895.